Optimind Pharma Corp.
OMND
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 98.90K | 85.30K | 81.70K | 81.90K | 72.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 98.90K | 85.30K | 81.70K | 81.90K | 72.40K |
| Cost of Revenue | 34.40K | 35.70K | 28.40K | 30.20K | 37.10K |
| Gross Profit | 64.50K | 49.60K | 53.30K | 51.70K | 35.40K |
| SG&A Expenses | 140.60K | 196.60K | 285.70K | 344.30K | 378.30K |
| Depreciation & Amortization | -- | -- | 0.00 | 3.70K | 9.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 174.90K | 232.20K | 314.00K | 378.20K | 424.70K |
| Operating Income | -76.00K | -146.90K | -232.30K | -296.20K | -352.20K |
| Income Before Tax | -85.80K | -157.10K | -670.40K | -740.30K | -817.70K |
| Income Tax Expenses | -- | -- | -6.50K | -6.50K | -6.50K |
| Earnings from Continuing Operations | -0.09 | -0.16 | -0.66 | -0.73 | -0.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.80K | -157.10K | -663.90K | -733.80K | -811.20K |
| EBIT | -76.00K | -146.90K | -232.30K | -296.20K | -352.20K |
| EBITDA | -- | -- | -98.10K | -164.40K | -274.60K |
| EPS Basic | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 433.61M | 445.79M | 439.88M | 428.18M | 417.00M |
| Average Diluted Shares Outstanding | 433.61M | 445.79M | 439.88M | 428.18M | 417.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |